Medicine and Dentistry
Ovarian Cancer
100%
Disease
88%
Cancer
62%
Gynecological Oncology
54%
Cancer Therapy
39%
Endometriosis
34%
Cervical Cancer
34%
Uterine Cancer
34%
Female Genital Tract Cancer
34%
Racial Disparity
32%
Socioeconomic Status
32%
Gynecological Surgery
29%
Surgical Technique
28%
Oncologist
28%
Homologous Recombination
27%
Hemoperitoneum
27%
Morcellation
27%
Antiangiogenic Therapy
27%
Congenital Adrenal Hyperplasia
27%
Endometrial Cancer
27%
Cancer Epidemiology
27%
Health Care Cost
27%
Adrenal Cortex Tumor
27%
PARP Inhibitor
27%
Surgery
27%
Lethality
27%
Cancer Survival
27%
Patient Compliance
27%
Adnexal Mass
27%
Heme
27%
Bevacizumab
27%
Uterus Sarcoma
20%
Pelvis
20%
Cancer Mortality
14%
Macrophage
13%
Sarcoma
13%
Angiogenesis Inhibitor
13%
Clinical Trial
12%
Malignant Neoplasm
12%
Multivariate Logistic Regression Analysis
12%
Hysterectomy
12%
Ovariectomy
10%
Neoplasm
10%
Retroperitoneal Lymph Node Dissection
10%
Predictive Assay
10%
Ovarian Tumor
10%
Surgical Approach
7%
Cancer Treatment
6%
Morcellator
6%
Medical Record
6%
Keyphrases
Gynecologic Oncology
81%
Ovarian Cancer
46%
Gynecologic Malignancies
36%
Surgical Procedures
28%
Gynecologic Surgery
28%
Gynecologic Oncologist
27%
International Collaboration
27%
Enhanced Recovery after Surgery (ERASĀ®)
27%
Racial Disparities
27%
Structured Report
27%
Surgical Care
27%
Socioeconomic Status
27%
Enhanced Recovery
27%
Endometriosis
27%
Ovarian Adrenal Rest Tumors
27%
Early-stage Ovarian Cancer
27%
Botswana
27%
NCCN Guidelines
27%
Disease-specific
27%
Financial Toxicity
27%
Laparotomy
27%
Clinical Practice Guidelines
27%
Predictors of Adherence
27%
Informed Consent
27%
Contraceptive Knowledge
27%
Spontaneous Hemoperitoneum in Pregnancy
27%
Treatment Adherence
27%
Adnexal Mass
27%
Anti-angiogenesis
27%
Bevacizumab
27%
Antiangiogenesis Therapy
27%
Labile Heme
27%
Chemotherapy
18%
Cervical Cancer
18%
High-volume Center
16%
Hispanic Patients
16%
Low SES
13%
Invasive Cervical Cancer
13%
Antiangiogenic Agents
13%
Logistic Regression Analysis
12%
Surgical Access
10%
White Patients
10%
Racial Classification
10%
Lymphadenectomy
10%
Initial Surgery
10%
Ovarian Malignancy
9%
Coping Strategies
9%
Multidisciplinary Clinic
9%
Comprehensive Score for Financial Toxicity
9%
Power Morcellators
9%